Review top news and interview highlights from the week ending February 3, 2023.
The clinical hold comes a few weeks after the company announced it was stopping enrollment in the phase 1/2 clinical trial.
Mehra and Subramanian discussed preclinical research with the investigational gene therapy SLS-004.
Shared insight on the benefits and drawbacks of using tumor-infiltrating lymphocyte therapy for treatment of solid tumors, as compared to chimeric antigen receptor (CAR) T-cell therapy.
Expert perspectives on the mechanism of action behind tumor-infiltrating lymphocyte (TIL) therapy and how it might address existing unmet needs in the treatment of solid tumors, including melanoma and non-small cell lung cancer.
The phase 1 clinical trial is the second of Frontera’s trials to begin dosing in 2023.